Nosocomial infection

Measures to Prevent and Control Transmission of Multidrug-Resistant Gram-Negative Bacilli (Excluding Carbapenemase-Producing Enterobacteriaceae) in Acute Care Settings in Québec

Gram-negative bacilli (GNB) are bacteria frequently encountered in clinical settings, both as normal flora and as pathogens in a variety of infections.

The use of antibiotics has led to the emergence of various resistance mechanisms and some of these bacteria are now resistant to several classes of antibiotics.

This document was created to help healthcare-associated infection prevention and control (IPC) teams identify major multidrug-resistant. Gram-negative bacilli (MDR-…

Professional practice guidelines

Prevention and control measures for Clostridium difficile in residential and long-term care facilities

Since August 2004, Clostridium difficile associated diarrhea (CDAD) has undergone ongoing surveillance in all Quebec hospitals with more than 1,000 admissions annually. The surveillance has monitored the evolution of CDAD levels in health care facilities and confirmed their decrease. From an average of 9.1 cases/10,000 patient days in 2005-2006, the average rate has dropped to 4.6 cases/10,000 patient days in 2016-2017 (SPIN, 2017). Clostridium difficile (C. difficile…
Professional practice guidelines

Prevention and control measures for Candida auris in health care facilities

Candida auris is an emerging microorganism that belongs to the yeast category. Increasingly, it is being found as a pathogen causing nosocomial fungal infections. First identified in Japan in 2009 in a sample from a patient’s auditory canal (Satoh et al., 2009; ECDC, 2016; Rock, 2017), it has since been identified in up to 17 countries, spread across at least 5 continents: Asia, Europe, Africa and the Americas (CDC, 2017a; Schwartz and Hammond, 2017). C. auris…
Professional practice guidelines

Vascular Access–Related Bloodstream Infections in Hemodialysis Patients Surveillance results: 2016-2017

From April 1st, 2016, to March 31st, 2017, 48 hemodialysis units took part in the surveillance of vascular access–related bloodstream infections (VARBSIs) in hemodialysis (HD) patients, for a combined total of 57,570 patient-periods (Table 1). Participating units reported 127 VARBSIs in 120 patients. Patient-periods involving a fistula account for 40.7% of patient-periods. The VARBSI incidence rate is 0.06 cases per 100…

Monitoring report

Central Line–Associated Bloodstream Infections in Intensive Care Units Surveillance results: 2016-2017

From April 1st, 2016, to March 31st, 2017, 69 intensive care units (ICUs) took part in surveillance of central line–associated bloodstream infections (CLABSIs), for a combined total of 135,114 catheter days (Table 1). Participating ICUs report 133 CLABSIs in 125 patients. Incidence rates are 0.91 per 1,000 catheter days in coronary ICUs, 0.62 in teaching adult ICUs, 0.46 in non-teaching adult ICUs, 2.16 in pediatric ICUs and…

Monitoring report

Hospital-Wide Healthcare-associated Bloodstream Infections Surveillance results: 2016-2017

From April 1st, 2016, to March 31st, 2017, 89 healthcare facilities took part in the hospital-wide surveillance of bloodstream infections (BSIs), for a combined total of 4,830,348 patient days (Table 1). Participating facilities reported 3,167 BSIs in 2,982 patients. The total incidence rate was 5.43 cases per 10,000 patient days. The incidence rate in 2016–2017 is stable compared with the average rate for 2012–2016…

Monitoring report

Clostridium difficile–Associated Diarrhea Surveillance results: 2016-2017

From April 1st, 2016 to March 31st, 2017, 95 healthcare facilities participated in the Clostridium difficile–associated diarrhea (CDAD) surveillance program, for a combined total of 5,022,104 patient days (Table 1). These participating facilities reported 2,330 healthcare-associated CDAD (HA-CDAD), either acquired during a current or previous hospitalization (categories 1a and 1b). The HA-CDAD incidence rate was 4.64 …

Monitoring report

Carbapenemase-Producing Gram Negative Bacilli Infections Surveillance results: 2016-2017

From April 1st, 2016, to March 31st, 2017, 82 healthcare facilities took part in the surveillance of carbapenemase-producing Gram negative bacilli (CPGNB) infections, for a total of 4,448,999 patient days (Table 1). These facilities reported 17 healthcare-associated CPGNB (HA-CPGNB) infections among patients who acquired their strain during a current or previous hospitalization (categories 1a and 1b). The incidence rate of HA-CPGNB infection was 0.04 per 10,000 patient…

Monitoring report

Vancomycin-Resistant Enterococci Infections Surveillance results: 2016-2017

From April 1st, 2016 to March 31st, 2017, 89 healthcare facilities took part in the surveillance of vancomycin-resistant enterococci (VRE) infections, for a combined total of 4,827,659 patient days (Table 1). These facilities reported 44 healthcare-associated VRE (HA-VRE) infections, either acquired during a current or previous hospitalization (categories 1a and 1b). The HA-VRE infection rate was 0.09 per 10,000 patient days. This incidence rate was down from 2015…

Monitoring report

Methicillin-Resistant Staphylococcus aureus Bloodstream Infections Surveillance results: 2016-2017

From April 1st, 2016 to March 31st, 2017, 89 healthcare facilities participated in the surveillance of methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections, for a combined total of 4,835,605 patient days (Table 1). Together, these facilities reported 66 cases of healthcare-associated MRSA bloodstream infections (HA-MRSA-BSI) acquired during a current or previous hospitalization (categories 1a and 1b…

Monitoring report